We are live on
!
Find out more
RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$810M
1-Year Est. Return
30.2%
This Fund
S&P 500
This Quarter
Est. Return
+7.6%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$696M
AUM Growth
+$65M
(+10%)
Cap. Flow
+$38.4M
Cap. Flow
% of AUM
5.52%
Top 10 Holdings %
Top 10 Hldgs %
28.66%
Holding
112
New
8
Increased
33
Reduced
36
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NovoCure
NVCR
|
+$15.7M |
| 2 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
+$12M |
| 3 |
Exelixis
EXEL
|
+$8.89M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$8.34M |
| 5 |
Sanofi
SNY
|
+$7.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$10.6M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$9.58M |
| 3 |
Supernus Pharmaceuticals
SUPN
|
+$7.12M |
| 4 |
ESPR
Esperion Therapeutics
ESPR
|
+$6.62M |
| 5 |
Biogen
BIIB
|
+$5.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.59% |
| 2 | Financials | 0.93% |
| 3 | Technology | 0.13% |
| 4 | Energy | 0.1% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
AB InBev
BUD
$165B
| $310K | 0.04% |
2,806
| – | – |
|
102
Qualcomm
QCOM
$168B
| $296K | 0.04% |
5,368
| – | – |
|
103
IBM
IBM
$220B
| $272K | 0.04% |
1,847
| – | – |
|
104
Tandem Diabetes Care
TNDM
$1.29B
| $187K | 0.03% |
23,400
| – | – |
|
|
MRTX
105
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $183K | 0.03% |
50,000
| – | – |
|
|
MTEM
106
DELISTED
Molecular Templates, Inc.
MTEM
| $79K | 0.01% |
1,221
| – | – |
|
|
ISEE
107
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $61K | 0.01% |
23,920
| – | – |
|
|
ANTH
108
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $41K | 0.01% |
25,000
| – | – |
|
109
Becton Dickinson
BDX
$48.8B
| – | – |
-5,125
| Closed | -$917K |
|
110
Intuitive Surgical
ISRG
$132B
| – | – |
-36,000
| Closed | -$3.07M |
|
111
Viatris
VTRS
$19B
| – | – |
-90,000
| Closed | -$3.51M |
|
|
TSRO
112
DELISTED
TESARO, Inc.
TSRO
| – | – |
-5,000
| Closed | -$769K |
|
Similar funds
PS
ACM
AR
KCP
BCM
OC
RIM
GCM
Rhenman & Partners Asset Management's Q2 2017 Portfolio in Review
As of Q2 2017, Rhenman & Partners Asset Management held 112 positions worth $696M, up 10% from $631M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Rhenman & Partners Asset Management deployed $38.4M of net new capital in Q2 2017, opening 8 new positions and adding to 33 existing holdings. Its largest new stake was NovoCure: 1,216,314 shares worth $21M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Amgen, an estimated $10.6M trimmed.
- Rhenman & Partners Asset Management's largest Q2 2017 buy was NovoCure: 1,216,314 shares worth $21M.
- Rhenman & Partners Asset Management added most to Exelixis in Q2 2017, an estimated $8.89M increase.
- Rhenman & Partners Asset Management's biggest Q2 2017 reduction was Amgen, cutting an estimated $10.6M.
- Rhenman & Partners Asset Management fully exited Viatris in Q2 2017, selling an estimated $3.51M.
- Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $696M portfolio in Q2 2017.
- Rhenman & Partners Asset Management opened 8 new positions and closed 4 in Q2 2017.
- Rhenman & Partners Asset Management's portfolio value rose 10% quarter-over-quarter to $696M.
Based on Rhenman & Partners Asset Management's 13F filing for Q2 2017, filed 11 Jul 2017.